Ghana first country in the world to approve 'world-changer' malaria vaccine R21 developed by University of Oxford

Good news!

"The vaccine - called R21 - appears to be hugely effective, in stark contrast to previous ventures in the same field.

Ghana's drug regulators have assessed the final trial data on the vaccine's safety and effectiveness, which is not yet public, and have decided to use it.

The World Health Organization is also considering approving the vaccine. ..."

"... The R21/Matrix-M malaria vaccine is a low-dose vaccine that can be manufactured at mass scale and modest cost, enabling as many as hundreds of millions of doses to be supplied to African countries which are suffering a significant malaria burden. ..."

Ghana first to approve 'world-changer' malaria vaccine - BBC News Ghana is the first country to approve a new malaria vaccine that has been described as a "world-changer" by the scientists who developed it.

R21/Matrix-M™ malaria vaccine developed by University of Oxford receives regulatory clearance for use in Ghana The University of Oxford-developed and Serum Institute of India PvT Ltd (SIIPL)- manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Ghana by the country’s Food and Drugs Authority.